Articles

An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;
Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;
Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA;
Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA;
Department of Pediatrics, Mayo Clinic, Rochester, MN, USA;
Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;
Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;
Centre de Reference pour la maladie de Rendu-Osler, Hospices Civils de Lyon, Lyon, France;
Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;
Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;
Division of Pulmonary, Critical Care, and Sleep Medicine, Augusta University, Augusta, GA, USA;
Division of Pulmonary, Critical Care, and Sleep Medicine, Augusta University, Augusta, GA, USA;
Div. of Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;
Div. of Interventional Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA;
Schneider Children's Medical Center of Israel, Tel Aviv University, Israel;
Schneider Children's Medical Center of Israel, Tel Aviv University, Israel;
Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA;
Dept. of Radiology, University of California San Francisco Medical Center, San Francisco, CA, USA;
Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA;
Division of Hematology, Massachusetts General Hospital, Boston, MA, USA;
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA
Haematologica Early view Jul 16, 2020 https://doi.org/10.3324/haematol.2020.261859